

Explore the Evolution of Controlled Terminology Standards

A Case Study Perspective


Priyanka Prabhakar, Christine Mathiesen



 CDISC regularly release new versions of its standards to improve data quality, interoperability, and efficiency of the data.

 Regulatory authorities require submissions that adhere to their guidelines, as it demonstrates a commitment to using the most up-to-date terminologies and ensures consistency across studies.

 Failure to update to the latest CDISC version, especially during the preparation of multistudy submissions, can lead to discrepancies and inconsistencies in terminologies across datasets, causing delays in the regulatory review process, potentially hindering their approval.



CT Requirements: Regulatory Insights

FDA Guidelines:

Latest version to be used at the start of the study **PMDA Guidelines:**

Refer PMDA's website for versions of the CDISC standards, controlled terminologies, and dictionaries that are accepted by the PMDA.

FDA Guidelines:



NEW

STUDIES

New version released post study commencement; most current version may be used. Impact to be described of the use of different versions on the study results

PMDA Guidelines:

Same version of CT be used within the same clinical study

FDA Guidelines:




Single version across studies, current version should be used at the time that data across studies are pooled.

PMDA Guidelines:


Same version for datasets of integrated analyses of multiple clinical studies, even if different versions were initially used. Detail the rationale for selecting a specific version and considerations for conversion in the data guide.


	Changes in Codelists	
35	50	
		Add
30	00	Remove

Effective management of changes requires active participation with careful consideration during public review, monitoring new releases, evaluating effects, and addressing potential challenges.



For instance, the Tanner staging code list underwent numerous changes over time, illustrating to develop mitigation strategies, organizations can effectively adapt and thrive in a constantly evolving standards and guidelines.





References : www.fda.gov www.pmda.go.jp evs.nci.nih.gov Ichm@novonordisk.com

Views expressed in the presentation by the presenter are personal and do not represent Novo Nordisk. No data or confidential information belonging to Novo Nordisk has been used in this presentation.